• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.

作者信息

Kochak G M, Page J G, Buchanan R A, Peters R, Padgett C S

机构信息

Kansas City Analytical Services, Shawnee, Kansas 66216, USA.

出版信息

J Clin Pharmacol. 1998 Feb;38(2):166-71. doi: 10.1002/j.1552-4604.1998.tb04406.x.

DOI:10.1002/j.1552-4604.1998.tb04406.x
PMID:9549648
Abstract

A 56-day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers. Steady state was achieved in 29 days including two dose escalations, and in an average of 15 days from the last dose adjustment. Twice-daily administration of 200 mg every 12 hours produced a 14% serum level fluctuation at steady state. After once-daily administration of 400 mg, a 27% serum level fluctuation was observed. The terminal-phase half-life after the last dose was 63 to 69 hours, which is consistent with the half-life of 52 to 60 hours found in single-dose studies. This result demonstrates that zonisamide is not an autoinducer. Serum oral clearance of 0.60 to 0.71 L/hr (0.121-0.132 mL/min/kg) was similar to that observed in other multiple-dose studies.

摘要

相似文献

1
Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.
J Clin Pharmacol. 1998 Feb;38(2):166-71. doi: 10.1002/j.1552-4604.1998.tb04406.x.
2
Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients.癫痫患者中唑尼沙胺剂量依赖性药代动力学的群体分析。
Biol Pharm Bull. 1994 Feb;17(2):323-6. doi: 10.1248/bpb.17.323.
3
Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.癫痫患者中稳态佐尼沙胺与丙戊酸之间不存在药代动力学相互作用。
Clin Pharmacokinet. 2005;44(5):517-23. doi: 10.2165/00003088-200544050-00005.
4
Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.唑尼沙胺在正常猎兔犬静脉注射和口服单剂量及口服多剂量后的处置与安全性。
J Vet Pharmacol Ther. 2008 Dec;31(6):544-53. doi: 10.1111/j.1365-2885.2008.00993.x.
5
Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs.唑尼沙胺在犬体内的药代动力学及与苯巴比妥的药物相互作用
J Vet Pharmacol Ther. 2008 Jun;31(3):259-64. doi: 10.1111/j.1365-2885.2008.00955.x.
6
Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers.健康中国志愿者口服唑尼沙胺后的群体药代动力学。
Int J Clin Pharmacol Ther. 2016 May;54(5):362-8. doi: 10.5414/CP202104.
7
Pharmacokinetics of zonisamide; saturable distribution into human and rat erythrocytes and into rat brain.
J Pharmacobiodyn. 1992 Aug;15(8):409-15. doi: 10.1248/bpb1978.15.409.
8
[Age dependency of the serum concentration of zonisamide].
No To Hattatsu. 1993 May;25(3):293-5.
9
Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy.唑尼沙胺:癫痫患儿的药代动力学、疗效及不良事件
Neuropediatrics. 2014 Dec;45(6):362-70. doi: 10.1055/s-0034-1387815. Epub 2014 Aug 18.
10
Pharmacokinetics of zonisamide following rectal administration to healthy dogs.唑尼沙胺经直肠给药于健康犬后的药代动力学
Am J Vet Res. 2016 Dec;77(12):1374-1380. doi: 10.2460/ajvr.77.12.1374.

引用本文的文献

1
Zonisamide: A Comprehensive, Updated Review for the Clinician.唑尼沙胺:给临床医生的全面、最新综述。
Neurol Clin Pract. 2024 Feb;14(1):e200210. doi: 10.1212/CPJ.0000000000200210. Epub 2023 Nov 10.
2
Integrating pharmacogenomics into clinical trials of hearing disorders.将药物基因组学整合到听力障碍的临床试验中。
J Acoust Soc Am. 2022 Nov;152(5):2828. doi: 10.1121/10.0015092.
3
Mechanisms and Pharmacotherapy for Ethanol-Responsive Movement Disorders.乙醇反应性运动障碍的机制与药物治疗
Front Neurol. 2020 Aug 25;11:892. doi: 10.3389/fneur.2020.00892. eCollection 2020.
4
Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.应用于唑尼沙胺药代动力学参数预测的药物代谢组学。
Metabolomics. 2018 May 9;14(5):70. doi: 10.1007/s11306-018-1365-5.
5
Treating epilepsy in the setting of medical comorbidities.治疗伴有合并症的癫痫。
Curr Treat Options Neurol. 2014 Jul;16(7):298. doi: 10.1007/s11940-014-0298-1.
6
Selection of antiepileptic drugs in older people.老年人抗癫痫药物的选择。
Curr Treat Options Neurol. 2014 Jun;16(6):295. doi: 10.1007/s11940-014-0295-4.
7
Update on once-daily zonisamide monotherapy in partial seizures.左乙拉西坦单药每日一次治疗部分性癫痫的最新进展。 (注:原文中的“zonisamide”应是“levetiracetam”的错误表述,按照正确的“levetiracetam”翻译为上述内容)
Neuropsychiatr Dis Treat. 2014 Mar 19;10:493-8. doi: 10.2147/NDT.S39152. eCollection 2014.
8
Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.新型抗癫痫药物(AEDs)的药物相互作用——第1部分:AEDs之间的药代动力学和药效学相互作用
Clin Pharmacokinet. 2013 Nov;52(11):927-66. doi: 10.1007/s40262-013-0087-0.
9
Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults.成人部分性癫痫发作单药治疗时一日一次服用唑尼沙胺的情况
Drug Des Devel Ther. 2013 May 14;7:397-402. doi: 10.2147/DDDT.S43612. Print 2013.
10
Zonisamide - a review of experience and use in partial seizures.唑尼沙胺——部分性癫痫发作的经验和应用综述。
Neuropsychiatr Dis Treat. 2006 Sep;2(3):269-80. doi: 10.2147/nedt.2006.2.3.269.